In a recent article from the NIH National Cancer Institute, concerning the January 2020 approval of Blueprint Medicine’s Ayvakit, The Life Raft Group is acknowledged in the section, “Capturing the Patient Experience.”
We are proud to have played a role in supporting the research involved in bringing a new treatment to market for Gastrointestinal Stromal Tumor( GIST) patients. Ayvakit adds an additional weapon to the arsenal of already approved treatments, with demonstrated efficacy for specific targets such as those with a PDGFRA mutation in exon 18.
The Life Raft Group’s ability to track and report patient data on treatment efficacy and side effects, both during and post-market, is invaluable to researchers and pharmaceutical companies as we strive to develop further treatments for GIST.
Excerpt from the article “Avapritinib Approved to Treat GIST with a Rare Gene Alteration”